Abbott boosts SpectRx holding to 13%:
This article was originally published in Clinica
Abbott Laboratories is to increase its shareholding in SpectRx, a device maker which is developing a non-invasive glucose monitoring device. Abbott has invested $5.25 million as part of an agreement with Norcross, Georgia-based SpectRx, begun in 1997, increasing its shareholding to 13% from just over 6%. SpectRx is also working with Abbott's rival, Roche Diagnostics, on a screening device based on fluorescence of the eye.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.